Jenburkt Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2026 ,inter alia, to consider and approve standalone unaudited ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jenburkt Pharmaceuticals has informed BSE that its Board of Directors will meet on Tuesday, 03 February 2026 at the registered office. The key agenda is to take on record the standalone unaudited financial results for the quarter and nine months ended 31 December 2025 (Q3 FY26). This is a standard regulatory intimation under SEBI LODR Regulation 29(1). No financial figures or outcomes have been disclosed yet — those will be shared after the board meeting. The filing was signed by Ashish Shah, Sr. VP & Company Secretary.
This is a routine pre-results announcement and carries no direct impact on the stock. Investors should watch for the actual Q3 FY26 numbers on or after 03 February 2026 to assess revenue growth, profitability, and margin trends.